Bioxcel Therapeutics, Inc. (BTAI)

Trade BTAI now with
1/7/2020 7:06:01 AM BioXcel Therapeutics Enrolls First Patient In Phase 1b/2 Study Of BXCL501
12/30/2019 7:10:09 AM BioXcel Therapeutics Begins Pivotal Phase 3 Studies Of BXCL501
12/3/2019 7:03:13 AM BioXcel Therapeutics Prepares To Initiate Pivotal Phase 3 Studies With BXCL501
11/14/2019 7:14:26 AM BioXcel Therapeutics Q3 Loss Per Share $0.57 Vs Loss $0.31 Last Year
9/26/2019 9:21:59 AM BioXcel Prices Public Offering Of 2.30 Mln Shares At $8.25 Per Share
9/4/2019 8:13:35 AM BioXcel Receives FDA Orphan Drug Designation For BXCL701 For AML Treatment
7/22/2019 6:02:39 AM BioXcel Therapeutics' BXCL501 Meets Primary Endpoint In Phase 1b Placebo-Controlled Trial
5/7/2019 8:08:42 AM BioXcel Therapeutics Q1 Net Loss $7.2 Mln Vs Loss Of $4.3 Mln Last Year
2/4/2019 8:07:49 AM BioXcel Therapeutics Expands Indication For Lead Neuroscience Asset
1/3/2019 8:25:27 AM BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data For Acute Treatment Of Agitation; Stock Surges